Quest Diagnostics CFO acquires 102 shares in award

Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.

Rhea-AI Filing Summary

Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.

Footnotes state the security represents an award of restricted share units and that the shares were acquired through a dividend reinvestment plan administered by his broker, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early.

Insider Trade Summary

Grant/Award: 102 shares

Grant/Award 1 txn

Insider SAMAD SAM

Role Executive Vice President & CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	102	$206.807	$21K

Holdings After Transaction: Common Stock — 33,478 shares (Direct)

Footnotes (2)

1. F1. Represents an award of restricted share units.
2. F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 102 shares Price per share: $206.807 per share Shares held after transaction: 33,478 shares

3 metrics

Shares acquired 102 shares Grant/award acquisition of common stock on July 22, 2026

Price per share $206.807 per share Reported transaction price for the July 22, 2026 acquisition

Shares held after transaction 33,478 shares Directly owned Quest Diagnostics common stock following the reported Form 4 transaction

Key Terms

restricted share units, dividend reinvestment plan, Rule 16a-6, Form 5

4 terms

restricted share units financial

"Footnotes describe the security as an award of restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

dividend reinvestment plan financial

"Shares were acquired pursuant to a dividend reinvestment plan administered by the broker."

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"The transaction is eligible for deferred reporting on Form 5 under Rule 16a-6."

Form 5 regulatory

"Eligible for deferred reporting on Form 5 under Rule 16a-6 but reported early."

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) CFO Sam Samad report on this Form 4?

Sam Samad reported acquiring 102 shares of Quest Diagnostics common stock on July 22, 2026 in a grant/award transaction at $206.807 per share, increasing his directly held stake to 33,478 shares according to the Form 4 data.

How many Quest Diagnostics (DGX) shares does Sam Samad hold after this reported transaction?

After the reported acquisition, Sam Samad directly holds 33,478 shares of Quest Diagnostics common stock. This figure reflects his ownership following the grant/award of 102 shares disclosed in the Form 4 filing for the July 22, 2026 transaction.

At what price were the Quest Diagnostics (DGX) shares acquired in Sam Samad’s July 22, 2026 transaction?

The 102 Quest Diagnostics shares were acquired at a reported price of $206.807 per share. This per-share value applies to the grant/award acquisition of common stock that is described in the Form 4 for Sam Samad.

What type of equity award did the Quest Diagnostics (DGX) CFO receive in this Form 4 filing?

Footnotes state the transaction represents an award of restricted share units. Although the security is labeled common stock, the note clarifies that the reported holding reflects restricted share units granted to Sam Samad as part of this acquisition.

Was Sam Samad’s Quest Diagnostics (DGX) transaction connected to a dividend reinvestment plan?

Yes. Footnotes explain the 102 shares reflect stock acquired under a dividend reinvestment plan administered by his broker. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6 but was instead reported early on this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:33 PM Accepted by SEC EDGAR 07/27/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAMAD SAM

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	07/22/2026		A	V	102(2)	A	$206.807	33,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted share units.

2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Sam Samad	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)